Fulcrum Therapeutics Inc ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $13.70 on 03/06/24, while the lowest value for the same period was recorded at $3.14 on 10/27/23.
52-week price history of FULC Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Fulcrum Therapeutics Inc’s current trading price is -35.84% away from its 52-week high, while its distance from the 52-week low is 179.94%. The stock’s price range during this period has spanned from $3.14 to $13.70. In the Healthcare sector, the Fulcrum Therapeutics Inc’s shares surpassed a trading volume of approximately 0.79 million for the day, which was noticeably lower compared to the average daily volume of 9.0.88 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Fulcrum Therapeutics Inc (FULC) has experienced a quarterly rise of 14.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 548.50M and boasts a workforce of 76 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 7.85, with a change in price of -0.52. Similarly, Fulcrum Therapeutics Inc recorded 746,152 in trading volume during the last 100 days, posting a change of -5.59%.
Examining FULC’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for FULC stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.03.
FULC Stock Stochastic Average
Today’s raw stochastic average for Fulcrum Therapeutics Inc over the last 50 days is 69.89%.This indicates a increase from the raw stochastic average of the past 20 days, which was 31.63%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 55.10% and 59.86%, respectively.
FULC Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The index has shown a price gain of 30.22% this year. Over the last six months, there has been a stronger performance of -7.96%. The price of FULC fallen by 2.69% during the last 30 days period. For the last 5-days stocks have slided -9.29%.
